GB0201508D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0201508D0
GB0201508D0 GBGB0201508.9A GB0201508A GB0201508D0 GB 0201508 D0 GB0201508 D0 GB 0201508D0 GB 0201508 A GB0201508 A GB 0201508A GB 0201508 D0 GB0201508 D0 GB 0201508D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
preparation
pharmaceutical compositions
derivatives
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0201508.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9929594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0201508(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0201508.9A priority Critical patent/GB0201508D0/en
Publication of GB0201508D0 publication Critical patent/GB0201508D0/en
Priority to EP10150442.1A priority patent/EP2194049B1/en
Priority to US10/502,291 priority patent/US7557105B2/en
Priority to EP07101787A priority patent/EP1783126A3/en
Priority to ES03731700T priority patent/ES2294293T3/es
Priority to PCT/EP2003/000613 priority patent/WO2003062220A1/en
Priority to PT03731700T priority patent/PT1470120E/pt
Priority to JP2003562099A priority patent/JP4213595B2/ja
Priority to PT101504421T priority patent/PT2194049E/pt
Priority to ES10150442.1T priority patent/ES2503734T3/es
Priority to CNA200910002666XA priority patent/CN101468984A/zh
Priority to CA2474104A priority patent/CA2474104C/en
Priority to CNB038027089A priority patent/CN100467461C/zh
Priority to KR1020047011382A priority patent/KR100778163B1/ko
Priority to AT03731700T priority patent/ATE380807T1/de
Priority to DE60318013T priority patent/DE60318013T2/de
Priority to BR0307058-1A priority patent/BR0307058A/pt
Priority to EP03731700A priority patent/EP1470120B1/en
Priority to MXPA04007130A priority patent/MXPA04007130A/es
Priority to KR1020077011065A priority patent/KR20070058019A/ko
Priority to IL162979A priority patent/IL162979A/en
Priority to JP2008208640A priority patent/JP5027076B2/ja
Priority to US12/478,082 priority patent/US20090239879A1/en
Priority to US12/781,430 priority patent/US20100222362A1/en
Priority to IL208399A priority patent/IL208399A/en
Priority to US13/176,289 priority patent/US20110294820A1/en
Priority to US14/330,404 priority patent/US20140323494A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
GBGB0201508.9A 2002-01-23 2002-01-23 Organic compounds Ceased GB0201508D0 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
GBGB0201508.9A GB0201508D0 (en) 2002-01-23 2002-01-23 Organic compounds
MXPA04007130A MXPA04007130A (es) 2002-01-23 2003-01-22 N-oxido de derivados de n-fenil-2-pirimidin-amina.
KR1020077011065A KR20070058019A (ko) 2002-01-23 2003-01-22 Ｎ-페닐-2-피리미딘-아민의 ｎ-옥사이드 유도체
CA2474104A CA2474104C (en) 2002-01-23 2003-01-22 N-oxides of n-phenyl-2-pyrimidine-amine derivatives
AT03731700T ATE380807T1 (de) 2002-01-23 2003-01-22 N-oxid von n-phenyl-2-pyrimidinaminderivaten
EP07101787A EP1783126A3 (en) 2002-01-23 2003-01-22 N-oxides of N-phenyl-2-pyrimidine-amine derivatives
ES03731700T ES2294293T3 (es) 2002-01-23 2003-01-22 N-oxido de derivados de n-fenil-2-pirimidinamina.
PCT/EP2003/000613 WO2003062220A1 (en) 2002-01-23 2003-01-22 N-oxyde of n-phenyl-2-pyrimidine-amine derivatives
PT03731700T PT1470120E (pt) 2002-01-23 2003-01-22 Derivados n-óxidos de n-fenil-2-pirimidino-amina
JP2003562099A JP4213595B2 (ja) 2002-01-23 2003-01-22 Ｎ−フェニル−２−ピリミジン−アミン誘導体のｎ−オキシド
PT101504421T PT2194049E (pt) 2002-01-23 2003-01-22 N-óxidos de derivados de n-fenil-2-pirimidina-amina
ES10150442.1T ES2503734T3 (es) 2002-01-23 2003-01-22 N-Óxidos de derivados de n-fenil-2-pirimidinamina
CNA200910002666XA CN101468984A (zh) 2002-01-23 2003-01-22 N-苯基-2-嘧啶-胺衍生物的n-氧化物
EP10150442.1A EP2194049B1 (en) 2002-01-23 2003-01-22 N-oxides of N-phenyl-2-pyrimidine-amine derivatives
CNB038027089A CN100467461C (zh) 2002-01-23 2003-01-22 N-苯基-2-嘧啶-胺衍生物的n-氧化物
KR1020047011382A KR100778163B1 (ko) 2002-01-23 2003-01-22 Ｎ-페닐-2-피리미딘-아민의 ｎ-옥사이드 유도체
US10/502,291 US7557105B2 (en) 2002-01-23 2003-01-22 N-oxides of N-phenyl-2-pyrimidine-amine derivatives
DE60318013T DE60318013T2 (de) 2002-01-23 2003-01-22 N-oxid von n-phenyl-2-pyrimidinaminderivaten
BR0307058-1A BR0307058A (pt) 2002-01-23 2003-01-22 N-óxidos de derivados de n-fenil-2-pirimidina-amina
EP03731700A EP1470120B1 (en) 2002-01-23 2003-01-22 N-oxyde of n-phenyl-2-pyrimidine-amine derivatives
IL162979A IL162979A (en) 2002-01-23 2004-07-12 4-[(4-methyl-4-oxido-1-piperazinyl)-methyl]-n-{4-methyl-3[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide, pharmaceutical compositions comprising it and use thereof for the preparation of medicaments for the treatment of a proliferative disorder
JP2008208640A JP5027076B2 (ja) 2002-01-23 2008-08-13 Ｎ−フェニル−２−ピリミジン−アミン誘導体のｎ−オキシド
US12/478,082 US20090239879A1 (en) 2002-01-23 2009-06-04 N-oxides of n-phenyl-2-pyrimidine-amine derivatives
US12/781,430 US20100222362A1 (en) 2002-01-23 2010-05-17 N-oxides of n-phenyl-2-pyramidine-amine derivatives
IL208399A IL208399A (en) 2002-01-23 2010-10-03 4-[(4-methyl-1-piperazinyl)-methyl]-n-{4-methyl-3[[4-(1-oxido-3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide,pharmaceutical compositions comprising it and use thereof for the preparation of a pharmaceutical composition for the treatment of a proliferative disorder
US13/176,289 US20110294820A1 (en) 2002-01-23 2011-07-05 N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives
US14/330,404 US20140323494A1 (en) 2002-01-23 2014-07-14 N-oxides of n-phenyl-2-pyrimidine-amine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0201508.9A GB0201508D0 (en) 2002-01-23 2002-01-23 Organic compounds

Publications (1)

Publication Number Publication Date
GB0201508D0 true GB0201508D0 (en) 2002-03-13

Family

ID=9929594

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0201508.9A Ceased GB0201508D0 (en) 2002-01-23 2002-01-23 Organic compounds

Country Status (15)

Country Link
US (5) US7557105B2 (enExample)
EP (3) EP2194049B1 (enExample)
JP (2) JP4213595B2 (enExample)
KR (2) KR20070058019A (enExample)
CN (2) CN101468984A (enExample)
AT (1) ATE380807T1 (enExample)
BR (1) BR0307058A (enExample)
CA (1) CA2474104C (enExample)
DE (1) DE60318013T2 (enExample)
ES (2) ES2503734T3 (enExample)
GB (1) GB0201508D0 (enExample)
IL (2) IL162979A (enExample)
MX (1) MXPA04007130A (enExample)
PT (2) PT1470120E (enExample)
WO (1) WO2003062220A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032872A1 (fr) * 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
CN1805748B (zh) * 2003-06-13 2010-05-26 诺瓦提斯公司 作为raf激酶抑制剂的2-氨基嘧啶衍生物
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
WO2007052849A1 (ja) * 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
CN101336237B (zh) * 2005-12-21 2015-09-30 诺华股份有限公司 作为fgf抑制剂的嘧啶基芳基脲衍生物
CA2652442C (en) * 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
US20090324718A1 (en) * 2006-09-01 2009-12-31 Ilan Zalit Imatinib compositions
EP2009008A1 (en) * 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
WO2008057291A2 (en) * 2006-10-26 2008-05-15 Sicor Inc. Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
CN101245061B (zh) * 2007-02-13 2012-09-19 天津天士力集团有限公司 N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺类一氧化氮供体型衍生物，制备方法及其用途
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
US8367686B2 (en) 2007-06-07 2013-02-05 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
WO2008153974A1 (en) 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
EP2081556A1 (en) * 2007-09-25 2009-07-29 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
WO2009060945A1 (ja) * 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. 血管新生阻害物質と抗腫瘍性白金錯体との併用
JP5399926B2 (ja) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
JP2011515685A (ja) * 2008-03-26 2011-05-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 基質結合ビーズを長期間保存する方法
CN101417995B (zh) * 2008-11-21 2012-06-06 陈依军 苯氧基嘧啶衍生物及其制备方法和用途
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103588754B (zh) * 2013-11-04 2015-05-27 遵义医学院 伊马替尼的制备方法
IL302218B2 (en) 2014-08-28 2024-10-01 Eisai R&D Man Co Ltd Methods for manufacturing high-purity lenvatinib and its derivatives
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
RU2750539C2 (ru) 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция для лечения опухоли
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN107573322A (zh) * 2017-09-06 2018-01-12 南京优科生物医药研究有限公司 伊马替尼双氮氧化物、其制备方法和用途
CN109761970B (zh) * 2019-01-26 2020-06-09 中国药科大学 一种蛋白靶向降解嵌合分子、制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607041A (en) * 1983-04-27 1986-08-19 Fisons Plc Antihypertensive 2-phenyl Hantzsch dihydropyridines
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (enExample) * 1992-04-03 1994-06-21 Ciba Geigy Ag
DE4444288A1 (de) * 1994-12-13 1996-06-20 Rainer Dr Med Etzel Verwendung von Weihrauch zur Behandlung der Alzheimer-Krankheit
CA2213700C (en) * 1995-02-28 2002-04-02 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments

Also Published As

Publication number Publication date
PT2194049E (pt) 2014-11-10
ATE380807T1 (de) 2007-12-15
ES2294293T3 (es) 2008-04-01
US20090239879A1 (en) 2009-09-24
EP1783126A3 (en) 2008-11-26
KR20070058019A (ko) 2007-06-07
KR20040081467A (ko) 2004-09-21
BR0307058A (pt) 2004-12-28
US7557105B2 (en) 2009-07-07
EP1470120A1 (en) 2004-10-27
CN100467461C (zh) 2009-03-11
US20140323494A1 (en) 2014-10-30
IL208399A0 (en) 2010-12-30
US20110294820A1 (en) 2011-12-01
WO2003062220A1 (en) 2003-07-31
US20100222362A1 (en) 2010-09-02
JP4213595B2 (ja) 2009-01-21
IL162979A (en) 2010-12-30
JP2005519908A (ja) 2005-07-07
JP2009051837A (ja) 2009-03-12
ES2503734T3 (es) 2014-10-07
PT1470120E (pt) 2008-03-03
CN1646519A (zh) 2005-07-27
JP5027076B2 (ja) 2012-09-19
EP1470120B1 (en) 2007-12-12
CA2474104A1 (en) 2003-07-31
CN101468984A (zh) 2009-07-01
KR100778163B1 (ko) 2007-11-28
DE60318013T2 (de) 2008-11-13
IL208399A (en) 2013-02-28
EP2194049B1 (en) 2014-08-13
EP1783126A2 (en) 2007-05-09
MXPA04007130A (es) 2004-10-29
CA2474104C (en) 2012-04-17
EP2194049A1 (en) 2010-06-09
US20050209452A1 (en) 2005-09-22
DE60318013D1 (de) 2008-01-24

Similar Documents

Publication Publication Date Title
GB0201508D0 (en) Organic compounds
GB0022438D0 (en) Organic Compounds
IL216579A0 (en) Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same
IL163090A (en) Nicotinamide derivates, pharmaceutical compositions comprising them and their use for manufacture of medicaments useful as p38 inhibitors
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CY1119309T1 (el) Συνδυασμενη χρηση toy (+)-1,4-διϋδρο-7-[(3s,4s)-3-meθoξy-4-(μεθυλαμινο)-1-πυρρολιδινυλ]-4-οξο-1(2-θειαζολυλ)-1,8-ναφθυριδιν-3-καρβοξυλικου οξεος και της κυταραβινης (ara-c) για την αγωγη της λευχαιμιας
WO2004006858A3 (en) Compounds, compositions, and methods employing same
IL173396A0 (en) Piperazine derivatives and their use as therapeutic agents
WO2005111002A3 (de) Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
ATE358485T1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
AU2003260436A1 (en) Pyrimidine compounds
WO2003024996A3 (de) Antibakterielle makrozyklen
AU2003245989A8 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
PL368040A1 (en) Substituted 4-aminocyclohexanol derivatives
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine
TW200503672A (en) 2-aminobenzoyl derivatives
PL1612210T3 (pl) Nowe analogi nitrobenzylotioinozyny
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
SG149051A1 (en) Nicotinic acetylcholine receptor ligands
SG149052A1 (en) Nicotinic acetylcholine receptor ligands
ATE327240T1 (de) 2ß OXO-VORUSCHARIN UND DERIVATEN

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)